Thursday, January 7, 2021

Can Ujjivan SFB outperform as normalcy returns with the vaccine?

Can Ujjivan SFB outperform as normalcy returns with the vaccine? Ujjivan SFB remains a key beneficiary should the vaccine rally get more widespread

from Moneycontrol Business News https://ift.tt/3s7sF8q
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Good news for Indian mutual fund investors: SpaceX could join Nasdaq 100 after 15 trading days

SpaceX’s expected entry into the Nasdaq-100 could give Indian investors indirect exposure through Nasdaq-linked mutual funds. Jefferies says...